protein

GCase

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about GCase: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

137Connections

3Hypotheses

2Analyses

50Outgoing

29Incoming

0Experiments

2Debates

Summary

A protein referenced in 5 knowledge graph relationships. Key connections: GBA1 (gene) encodes; maintains lysosomal_function (mechanism); alpha_synuclein_aggregation (mechanism) inhibits.

View on Wiki →

No AI portrait yet

🔬 Protein Info

Gene Symbol	GCASE
Primary Expression	Substantia Nigra
Pathways	Alpha-Synuclein, Unfolded Protein Response, Er Stress, Mitochondrial Function
GeneCards	GCASE
Human Protein Atlas	GCASE
Associated Diseases	alzheimers, disease, oxidative_stress
Known Drugs/Compounds	ambroxol, small molecule chaperones
Interactions	HSP70, TFEB, TRPML1
KG Connections	64 knowledge graph edges
Databases	GeneCards UniProt NCBI Gene HPA STRING

Wiki Pages (6)

Knowledge base pages for this entity

Pathway Diagram

graph TD
    GCASE["GCASE"]
    GCASE -->|"cleaves"| Glucocerebrosides["Glucocerebrosides"]
    GCASE -->|"causes"| Senescence["Senescence"]
    GCASE -->|"causes"| Parkinson["Parkinson"]
    GCASE -->|"causes"| Neurodegeneration["Neurodegeneration"]
    GCASE -->|"causes"| Aging["Aging"]
    GCASE -->|"interacts"| Ms["Ms"]
    GBA["GBA"] -->|"encodes"| GCASE
    PLIN2["PLIN2"] -->|"causes"| GCASE
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"causes"| GCASE
    NEURON["NEURON"] -->|"causes"| GCASE
    AGING["AGING"] -->|"causes"| GCASE
    PARKINSON["PARKINSON"] -->|"activates"| GCASE

Outgoing (108)

Target	Relation	Type	Str
alpha_synuclein_aggregation	contributes_to	mechanism	0.95
alpha_synuclein_aggregation	interacts_with	mechanism	0.95
Gaucher disease	implicated_in	unknown	0.95
alpha_synuclein_aggregation	involved_in	mechanism	0.95
lysosomal_function	involved_in	mechanism	0.95
lysosomal_dysfunction	involved_in	mechanism	0.95
protein aggregation	associated_with	mechanism	0.90
Parkinson's_disease	implicated_in	unknown	0.90
autophagy	involved_in	pathway	0.90
lysosomal_clearance	involved_in	unknown	0.90
parkinsons_disease	increases_risk	unknown	0.90
lysosomal_dysfunction	associated_with	mechanism	0.90
lysosomal_clearance	mediates	unknown	0.90
Glucocerebrosides	cleaves	compound	0.90
mitochondrial_dysfunction	associated_with	mechanism	0.90
energy metabolism	modulates	unknown	0.90
alpha_synuclein_aggregation	inhibits	mechanism	0.90
lysosomal_dysfunction	contributes_to	mechanism	0.85
mitochondrial_dysfunction	contributes_to	mechanism	0.85
protein aggregation	involved_in	mechanism	0.85
protein aggregation	contributes_to	mechanism	0.85
mitochondrial_dysfunction	inhibits	mechanism	0.85
Synucleinopathies	risk_factor_for	disease	0.85
lysosomal_protein_degradation	mediates	unknown	0.85
oxidative_stress	causes	phenotype	0.85
autolysosome pathway	involved_in	unknown	0.85
alpha_synuclein_aggregation	associated_with	mechanism	0.85
alzheimer_disease	biomarker_for	disease	0.85
glymphatic_clearance	involved_in	mechanism	0.85
mitochondrial transfer	involved_in	mechanism	0.85
HSP70	interacts_with	protein	0.85
oxidative stress	contributes_to	mechanism	0.80
protein aggregation	inhibits	mechanism	0.80
mitochondrial DNA release	contributes_to	mechanism	0.80
LRRK2	interacts_with	protein	0.80
oxidative_stress	associated_with	phenotype	0.80
protein_aggregation	modulates	mechanism	0.80
mitochondrial_dysfunction	involved_in	mechanism	0.80
TFEB	associated_with	protein	0.75
protein aggregation	modulates	mechanism	0.75
microglial_activation	associated_with	mechanism	0.75
alpha_synuclein_aggregation	modulates	mechanism	0.75
TFEB	interacts_with	protein	0.75
oxidative_stress	modulates	phenotype	0.75
glymphatic_clearance	modulates	mechanism	0.75
TRPML1	interacts_with	protein	0.70
TRPML1	associated_with	protein	0.70
phagocytosis	involved_in	mechanism	0.70
alzheimers	associated_with	disease	0.70
oxidative stress	modulates	mechanism	0.70

Incoming (29)

Source	Relation	Type	Str
GBA1	expresses	gene	1.00
TRIP12	interacts_with	unknown	0.95
TRIP12	associated_with	unknown	0.95
GBA	encodes	gene	0.95
LPC	inhibits	unknown	0.92
TRIP12	degrades	unknown	0.90
Ambroxol	activates	drug	0.90
COMMD3	modulates	unknown	0.90
HDAC3 inhibition	modulates	mechanism	0.80
HSP70	interacts_with	protein	0.80
TFEB	modulates	protein	0.75
small molecule chaperones	modulates	drug	0.75
GPR32	modulates	protein	0.75
HSP70	modulates	protein	0.70
ambroxol	activates	drug	0.70
oxidative_stress	inhibits	phenotype	0.70
GBA	cleaves	entity	0.60
NEURODEGENERATION	causes	gene	0.60
PARKINSON	causes	gene	0.60
BIP	activates	gene	0.60
NEURON	causes	gene	0.60
AGING	causes	gene	0.60
GBA1 VARIANTS	causes	gene	0.60
GBA	degrades	gene	0.60
GBA1	causes	gene	0.60
PLIN2	causes	gene	0.60
ALPHA-SYNUCLEIN	causes	gene	0.60
PARKINSON	activates	gene	0.60
GBA1	associated_with	gene	0.50

Targeting Hypotheses (3)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
GBA1/GCase restoration to reduce alpha-synuclein pathology i	0.760	neurodegeneration	Test
Glucosylceramide Accumulation from GCase Deficiency Disrupts	0.700	neurodegeneration	-
VPS35 Retromer Dysfunction Creates a GCase Trafficking Bottl	0.700	neurodegeneration	-

Mentioning Analyses (2)

Scientific analyses that reference this entity

What is the therapeutic window between GCS inhibition efficacy and systemic toxi

neurodegeneration | 2026-04-11 | 0 hypotheses

GBA-Synuclein Loop Therapeutics for PD

neurodegeneration | 2026-04-01 | 8 hypotheses Top: 0.525

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (2)

Multi-agent debates referencing this entity

The debate identified systemic toxicity as a major concern for glucosylceramide

closed · Rounds: 4 · Score: 0.50 · 2026-04-20

How to break the GBA-alpha-synuclein bidirectional loop for Parkinson's Disease

closed · Rounds: 4 · Score: 0.90 · 2026-04-06

Related Research

Hypotheses and analyses mentioning GCase in their description or question text

No additional research found